Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS665-TPS665
◽
Keyword(s):
Phase 2
◽
2018 ◽
Vol 174
(2)
◽
pp. 433-442
◽